1 Applying GAN-based data augmentation to improve transcriptome-based 2 prognostication in breast cancer 3 Working title: Data augmentation for improved breast cancer prognostication 4 5 Cristiano Guttà^{1,*}, Christoph Morhard², Markus Rehm^{1,3,*} 6 7 1 Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 8 9 Stuttgart, Germany 10 2 ProKanDo GmbH, Elfriede-Breitenbach-Straße 38a, 71640 Ludwigsburg, Germany 3 Stuttgart Research Center Systems Biology, University of Stuttgart, Nobelstrasse 15, 70569 11 12 Stuttgart, Germany 13 14 *To whom correspondence should be addressed: Prof Dr Markus Rehm Cristiano Guttà Institute of Cell Biology and Immunology Institute of Cell Biology and Immunology University of Stuttgart University of Stuttgart Allmandring 31, 70569 Stuttgart, Germany Allmandring 31, 70569 Stuttgart, Germany E-mail: markus.morrison@izi.uni-stuttgart.de E-mail: cristiano.gutta@izi.uni-stuttgart.de ORCID ID 0000-0001-6149-9261 15 16 **Abstract** 17 Established prognostic tests based on limited numbers of transcripts can identify high-risk 18 breast cancer patients yet are approved only for individuals presenting with specific clinical 19 features or disease characteristics. Deep learning algorithms could hold potential for 20 stratifying patient cohorts based on full transcriptome data, yet the development of robust 21 classifiers is hampered by the number of variables in omics datasets typically far exceeding 22 the number of patients. To overcome this hurdle, we propose a classifier based on a data

augmentation pipeline consisting of a Wasserstein generative adversarial network (GAN) with gradient penalty and an embedded auxiliary classifier to obtain a trained GAN discriminator (T-GAN-D). Applied to 1244 patients of the METABRIC breast cancer cohort, this classifier outperformed established breast cancer biomarkers in separating low- from high-risk patients (disease specific death, progression or relapse within 10 years from initial diagnosis). Importantly, the T-GAN-D also performed across independent, merged transcriptome datasets (METABRIC and TCGA-BRCA cohorts), and merging data improved overall patient stratification. In conclusion, GAN-based data augmentation therefore allowed generating a robust classifier capable of stratifying low- vs high-risk patients based on full transcriptome data and across independent and heterogeneous breast cancer cohorts.

Introduction

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Breast cancer is the tumor with the highest incidence in women, accounting for 2.3 million new diagnoses and 685,000 deaths worldwide in 2020. According to the World Health Organization, nearly eight million patients were diagnosed with breast cancer in the five years before 2020, making it the most prevalent tumor disease worldwide ¹. In current clinical practice, the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is determined by immunohistochemistry (IHC), with the expression patterns defining to which molecular subtype (luminal A, luminal B, HER2 positive or enriched and triple-negative breast cancer) individual tumors belong. Prognosis differs between these subtypes, and subtyping informs treatment plans in patients in which surgical resection of the tumor alone is insufficient ². However, substantial response heterogeneities to the current standard of care treatments can be observed in populations of breast cancer patients³, highlighting the need for additional prognostic markers that could serve to identify high risk patients that could instead benefit from alternative treatments or for which the burden from inefficient standard of care treatments could be avoided ⁴. Various multi-gene activity tests based on transcript abundance have been developed to assist in the clinical management of breast cancer (e.g. Oncotype DX⁵, MammaPrint ^{6,7}, Prosigna ^{8,9}, OncoMasTR¹⁰) and received regulatory approval as prognostic tests ¹¹. Despite the prognostic value of these assays, their use is restricted to only subsets of patients with specific clinical characteristics (e.g. cancer stage, receptor or lymph node status, tumor size, menopause state, age group) ^{12–14}. It would therefore be desirable if more generally applicable prognostic tests based on transcriptome data could be developed. The rapid advances in high-throughput sequencing technologies make tumor transcriptome data from larger patient cohorts increasingly available. The accessibility of -omics databases and companion clinical information now also encourages the application of deep learning (DL) methods to the oncology field, with the aim of learning and extracting features within

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

large scale data that are not readily accessible by classical statistical and pattern recognition approaches. It is hoped that from DL-based methods tools can be developed that can aid in further advancing cancer diagnosis, prognosis or predicting treatment efficacy in the future ¹⁵. DL algorithms such as convolutional neural networks (CNN) were originally applied for image analysis but could be successfully repurposed to take non-image objects as input, such as RNA-seq data ¹⁶. One of the major pitfalls when applying DL models to transcriptome datasets is the typical imbalance between the number of quantified mRNAs (high) and the number of patients (low), which can lead to overfitting when solving classification tasks ¹⁷. In addition, low numbers of samples or patients that represent one category (e.g. good prognosis) come at the risk of capturing patterns that are not robust when applied to larger populations ¹⁸. Feature selection strategies ¹⁹, under- and over-sampling ²⁰ are three strategies that may help mitigating effects arising from imbalanced source data. An alternative strategy lies in novel data augmentation approaches, such as generative adversarial networks (GANs), by which source datasets can be enriched with artificially generated additional data. GANs are typically applied to imaging data and are composed of two subnetworks, the generator and the discriminator. While the former produces synthetic images, the latter is challenged to discriminate fake vs. real images. Reiterating this process, the generator learns to produce images with features that can no longer be separated from the real images by the discriminator, with these generated images then enriching the source dataset ²¹. In comparison to other generative models, GANs are currently preferred due to their computational speed and the quality of the generated images ²². In addition, they exhibit a lower risk of overfitting classifiers and are less susceptible to the impact of non-pertinent image features (such as brightness) when enriching training data with synthetic images ²³. For example, GANs have been applied in the medical field to generate synthetic magnetic resonance, computed tomography or positron emission tomography images ²⁴. Aside from image-data, different

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

GAN implementations were also successfully applied to transcriptome data for cancer diagnosis ^{25,26}, staging ²⁷ and subtyping ²⁸. The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, hereafter MB) ²⁹ and The Cancer Genome Atlas – Breast Invasive Carcinoma (TCGA-BRCA, hereafter TCGA) ³⁰ cohorts represent two of the largest and most exhaustively annotated breast cancer datasets, including, in addition to mRNA expression data, features such as patient demographics, cancer staging, receptor statuses, and follow-up information such as survival times. Despite not being directly interoperable due to different sequencing technologies, these datasets can serve as use cases to test new DL-based prognostication approaches. In this study, we therefore set out to develop a prognostication framework that used the trained discriminator of a GAN architecture as a standalone classifier and compared its performance to classical breast cancer biomarkers and a classical CNN. Materials and methods **Data integration** The METABRIC (MB) dataset was used to develop the prototype network implementation. Transcriptome data (median Z-scores), overall survival (OS), disease specific survival (DSS) and associated clinical records were downloaded from cbioportal.org ^{31,32}. The dataset was integrated with locoregional and distant recurrence information retrieved from Rueda et al. 33 and Risk of Recurrence – Proliferation (ROR-P) scores reported by Xia et al ⁹. Clinical records, OS, DSS and progression free interval (PFI) of the validation TCGA-BRCA cohort (TCGA) were integrated from cbioportal.org ^{31,32} and Liu et al. 2018 ³⁴, respectively. To merge the mRNA expression data of the two cohorts, normalized transcriptome datasets were downloaded using the R package MetaGxBreast ³⁵. The transcript amounts were rescaled as described by Gendoo et al. ³⁵ so that the 2.5 percentile corresponds to -1 and the 97.5

percentile corresponds to +1. Subsequently, transcripts overlapping between the two cohorts

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

and with quantitative information missing in not more than five patients were retained, resulting in transcripts for m = 14042 genes. The R script used to download and rescale the datasets is available in the Zenodo repository ³⁶. Inclusion criteria and category definition Both cohorts were filtered to exclude normal-like subtype samples ^{9,37,38} and patients for which less than 10 years of follow-up time from diagnosis were available. Low and high risk categories were defined according to published clinical records^{8,9} as follows: high risk patients: o MB cohort: disease specific death, locoregional or distant recurrence event recorded before 10 years from initial diagnosis; o TCGA cohort: disease specific death, progression, local recurrence or distant metastases before 10 years from initial diagnosis. low risk patients: none of the above-mentioned events recorded before 10 years from initial diagnosis. In total, 1248 patients of the MB cohort (n = 567 high risk, n = 681 low risk) and 165 patients of the TCGA cohort (n = 132 high risk, n = 33 low risk) satisfied the inclusion criteria. Four patients from each cohort were excluded after merging due to insufficient expression data. Survival analysis and accuracy Log-rank testing was used to compare predicted low vs high risk patients over a follow-up time of 10 years. Kaplan-Meier (KM) survival curves were computed using GraphPad Prism 8 (GraphPad Software, San Diego, CA). The area between the curves (ABC) displayed on the KM graphs for the pooled predictions was calculated as follows: Low risk AUC minus Predicted low risk AUC; Predicted low risk AUC minus Predicted high risk AUC;

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Predicted high risk AUC minus High risk AUC. The ABCs values are shown on the graphs in the abovementioned order top to bottom. The AUC was computed using GraphPad Prism 8 (GraphPad Software, San Diego, CA). Univariate and multivariate hazard ratios were calculated using the function *coxph* from the R's library *survival* (v. 3.4.0, https://www.r-project.org/). **GAN** architecture The architecture was based on a Wasserstein ³⁹ GAN ²¹ with gradient penalty ⁴⁰ and an auxiliary classifier 41 as a variant of a conditional GAN implementation 42, yielding a AC-WGAN-GP architecture. The Wasserstein loss was implemented to reduce vanishing gradients and mode collapse ⁴³ in the early phases of the training when the discriminator outperformed the generator. Stability was improved by exchanging the weights clipping approach described in Arjovsky et al. ³⁹, with the gradient penalty described in Gulrajani et al. ⁴⁰. To create a conditional GAN, an auxiliary classifier network was implemented ⁴¹, resulting in a more stable training process and reduced mode collapse compared to the standard conditional GAN approach, supplying labels to both discriminator and generator ⁴³. A zvector of size 250 was fed as input for the generator. Following good training practice 44, strided convolutions with step size 2, batch normalization and LeakyRELU as activation function were used. Since using batch normalization in the discriminator and/or the ADAM optimizer led to an unstable training process, batch normalization ⁴⁵ was only used in the generator, and RMSprop was selected as the activation function. A shallow network consisting of two layers in both the discriminator and the generator led to the most stable training process, due to the smaller number of trainable parameters compared to deeper networks. Hyperparameters were tuned empirically, selecting 1000 epochs for the training process. Three "discriminator-only" training runs were performed before each full network

training run, and the generated pictures were subsequently smoothed with a final convolution

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

layer with one filter and stride size of 1. The GAN architecture generated expression data of size 144x144 when using the entire transcriptome dataset of the MB cohort alone (m = 18543genes) and 120x120 when merging the MB and TCGA cohorts (m = 14042 genes). In the latter setting, expression profiles with less than 14,440 transcripts were filled with random values, leading to better convergence. The resulting trained GAN Discriminator (T-GAN-D) was then used as an independent classifier to discriminate low and high risk patients. The Python code and the input files used to generate the predictions are available in the Zenodo repository ³⁶. **CNN** architecture As the performance of the CNN implemented as the GAN's discriminator showed satisfactory performance, a similar architecture was used as a benchmark classifier. Batch normalization was employed to ensure shorter training periods and RELU was used as the activation function. A fixed training length of 1250 epochs was set due to the limited sample size and to generate comparable iterations. The accuracy of both classifiers was calculated dividing the number of correct classifications by the total number of classifications performed. **Results** The METABRIC and BRCA-TCGA cohorts lend themselves as use cases for data augmentation and development of prognostication classifiers One of the major challenges of machine learning applied to -omics data and companion medical records is the imbalance between the high amounts of variables compared to the limited number of patients available. Even in the case of breast cancer, one of the most frequent and widely studied malignant neoplasms, this limitation is apparent in the two major

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

public transcriptome datasets, namely the MB cohort (n = 1904 patients, m = 18543transcripts) and the TCGA cohort (n = 1101 patients, m = 20532 transcripts). This imbalance is exacerbated for prognostic analyses that require long-term (10 years) follow-up information and the application of further exclusion criteria (see methods), reducing cohort sizes to n = 1248 and n = 165, respectively (**Fig. 1A, B**). Both cohorts behaved notably different, with patients in the MB cohort on average having an overall substantially better prognosis in overall survival and relapse-free, progression-free or disease specific survival (Fig. 1C, D). This is likely attributable to the MB dataset largely consisting of stage I and stage II patients (89.5% of patients with reported disease stage at diagnosis), whereas stage III and IV patients are more prominent in the TCGA dataset (40.4% of individuals with available disease stage at diagnosis). Despite these differences, the high risk subgroups of both cohorts showed comparable median survival times (MB = 31.9 months [Fig. 1E], TCGA = 26.3 months [Fig. **1F**]). Due to the limited sizes of these cohorts, they lend themselves as suitably challenging use-cases for applying and testing data augmentation for improving prognostication. In particular, we set out to implement a classifier based on a data augmentation network for improved patient stratification in the MB cohort, to subsequently validate robustness and transferability by integrating the independent TCGA cohort. A trained GAN discriminator robustly identifies low and high risk breast cancer

patients

To tackle the problem of data scarcity, we implemented a GAN architecture to augment transcriptomic data of the MB cohort and tested the performance of a trained discriminator in stratifying breast cancer patients. First, individual patient transcriptome profiles were rescaled and converted into arrays of pixels (Fig. 2A i) in order to use these images as an input for the GAN. Independent of these true patient data, the generator created images representing the

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

transcript profiles of synthetic hypothetical patients together with their category (low or high risk) (Fig. 2A ii). After being exposed to a fraction of the real transcriptome images and associated categories, its adversary, the discriminator network then tried to distinguish fake from real transcriptome images for high or low risk patients (Fig. 2A iii). Reiterating this training process over 1000 epochs, the generator learned to create realistic synthetic transcriptome images for high and low risk categories, which then could be used to augment the original MB cohort data. Associated characteristics of this process (discriminator loss, discriminator class loss, generator loss) are shown in **Supplementary Fig. 1**. Using this approach, the discriminator learned to identify features relevant for the risk category definition, aided by the synthetic profiles that enriched the real training data at each epoch. The trained GAN discriminator (T-GAN-D) resulting from this process then was used as a standalone classifier to categorize images from the test fraction of the cohort into the high or low risk categories (Fig. 2A iv), thus prognosticating patient outcome. We first implemented and tested the T-GAN-D for its prognostic capability using follow-up and mRNA expression data of the prototyping MB cohort, consisting of n = 1248 individuals and m = 18543 genes. Within this cohort, we independently cross-validated (CV) five-fold with randomly composed training data. Kaplan-Meier curves and log rank testing for each run yielded significant class separations in 4 out of 5 iterations (Fig. 2B, Supplementary Fig. 2A). Pooling the results so that each patient of the MB dataset was present once in the survival analysis, the T-GAN-D separated high and low risk patients with high statistical significance (p-value = 2.71E-12) (**Fig. 2C**). To obtain a reference performance baseline, a classical CNN was challenged with the same task, using the same training and test sets for each iteration. The CNN yielded class separations with a p<0.05 in only two out of five iterations (Fig. 2D, Supplementary Fig. 2B). In the pooled comparison, the CNN performed well yet failed to outperform the T-GAN-D in separating low vs. high risk patients (**Fig.2E**, **Supplementary Table 1**). These results therefore demonstrate that the reiterative learning

process of a GAN to train its discriminator and use it as an independent classifier provides a more robust and slightly improved patient stratification than a classical DL approach.

Introducing and independent cohort improves MB patient classification

A common limitation of predictors and classifiers is their limited robustness and transferability to independent datasets. This might arise from overfitting or overtraining within the initial cohort but also from heterogeneity and batch effects between source datasets. For validating our approach further, we therefore merged the mRNA expression data of the MB and TCGA cohorts, which originally were quantified with bead-based microarray technology (Illumina Human V3) or RNA-Seq (Illumina HiSeq) platforms respectively ⁴⁶, by rescaling the expression of transcripts overlapping between the two cohorts (m = 14042). We then retrained the discriminator using the entire TCGA data plus a fraction of the MB data from the merged dataset and generated predictions on an independent subset of MB patients (**Fig. 3A**), using five-fold cross-validation. The T-GAN-D again separated patients into low and high-risk categories with high statistical significance (Fig. 3B, Supplementary Fig. 3A). The CNN trained and tested with the same data performed similarly well (Fig. 3C, **Supplementary Fig. 3B**). The T-GAN-D trained on the merged and reduced dataset also showed improved accuracy when compared to all settings where both a CNN or the GAN were trained on the full or reduced MB dataset alone (Supplementary Table 1, 2). Therefore, in our setting, rescaling and converting transcriptome profiles into images was sufficient to successfully merge the two cohorts without the need for further preprocessing steps and allowed to stratify patients into high and low risk classes.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

cancer cases.

The T-GAN-D outperforms classical outcome predictors and accurately stratifies early stage patients into risk categories We next compared the performance of CNN and GAN based classifications to other established clinical markers in breast cancer. These included a scoring system based on a multi-transcript signature (Risk-of-recurrence - proliferation, [ROR-P]), estrogen receptor status (ER), human epidermal growth factor receptor 2 status (HER2), and progesterone receptor status (PR). Likewise, tumor staging was included, yet was available for only 911 out of 1248 patients of the MB cohort. The hazard ratios (HR) obtained from a univariate analysis were comparable for ROR-P, HER2 or tumor staging as classifiers, and similar HRs were also obtained for the CNN and T-GAN-D classifiers developed from only the MB transcriptome dataset (Fig. 4A). Interestingly, the T-GAN-D classifier resulting from the merged cohort data returned a mean HR>2.0 (+/- 0.4), thereby surpassing all other markers. This feature was even more pronounced in a multivariate analysis including ER, HER2 and PR biomarkers (Fig. **4B**). When reducing the MB cohort to those patients for which staging information was available, HRs based on staging and T-GAN-D were comparable (Fig. 4C). To test whether both classifiers might be redundant, we performed a T-GAN-D based survival analysis within the tumor stage I and stage II subcohorts, which dominate the MB dataset. T-GAN-D based classification allowed separating high and low risk patients within both tumor stages (Fig. 4D, E), indicating non-redundancy of the T-GAN-D classification to tumor staging information. Taken together, these results show that training through data augmentation can enhance the prognostic performance of DL classifiers, and in this case surpasses individual classical biomarkers. In addition, the T-GAN-D performed well in prognostication of early stage breast

The T-GAN-D stratifies TCGA patients despite these being scarcely represented

After observing that introducing TCGA patients into the training set of the T-GAN-D did not degrade, but improved the stratification of MB patients, we tested the performance of the classifier on the smaller TCGA dataset. To do this, we trained the discriminator using the entire MB data plus a fraction of the TCGA data from the merged dataset and generated predictions on an independent subset of TCGA patients (**Fig. 5A**), using five-fold cross-validation. The T-GAN-D correctly predicted 78% of the cases (**Fig. 5B**, **Supplementary Fig. 4**, **Supplementary Table 3**). In contrast, when trained on the MB dataset alone, the T-GAN-D was not able to separate high and low risk patients (**Fig. 5C**, **Supplementary Fig. 4**), achieving an overall accuracy of only 43% (**Supplementary Table 3**). Therefore, the addition to the training set of a comparably small number of TCGA patients (n = 129) to the larger MB cohort (n = 1244) was sufficient to drastically improve the performance of the T-GAN-D predicting TCGA patient outcome. This demonstrates that even if the training set is largely dominated by patients belonging to one cohort, the introduction of a limited number of samples of a second, differently balanced dataset appears sufficient to possibly capture relevant patterns that contribute to achieving improved prognostic performance.

Discussion

The increasing availability and routine acquisition of large scale genomic data encourage the repurposing and application of AI to the field of oncology in order to identify novel means for improved and personalized prediction of prognosis ⁴⁷. In this study, we developed a DL-based tool to stratify high vs. low risk breast cancer patients according to full transcriptome profiles. Using the MB and TCGA cohorts as use cases, we converted expression data into images and used the trained discriminator of our GAN architecture as a standalone prognostic classifier. Our results show that the T-GAN-D performed better than classical outcome predictors and maintained robust performance when merging the two cohorts.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

AI has already been applied to breast cancer based on different classes of data, to inform diagnosis, treatment planning and prognosis ^{48,49}. For example, pattern recognition and data augmentation proved to be promising approaches to assist in generating accurate diagnoses from mammography images ^{50,51}. Transcriptome data were also employed to develop MLbased analysis pipelines for breast cancer subtyping, diagnosis, patient stratification and identification of altered pathways ⁵², and these techniques may improve the accuracy of cancer prognosis in the future. However, shortcomings must be taken into account, as applicable also to currently available breast cancer datasets. When dealing with low sample size - high dimension datasets such as the MB and TCGA cohorts, common DL classification algorithms such as neural networks may be prone to overfitting ⁵³. Multi-gene signatures based on the expression of a lower number of transcripts may circumvent this problem, but are applicable only to subsets of patients with specific clinical characteristics ^{11–14}. To tackle these problems, we aimed at developing a more universally applicable algorithm that takes advantage of GAN's data augmentation and generalizing capability. In our training strategy, the T-GAN-D was exposed not only to a subset of original data, but also to the synthetic patients generated by the generator in each epoch. This approach for the augmentation of training data was demonstrated before to aid a discriminator in learning hidden features and correlations ^{54,55}. When compared to a classic CNN, the T-GAN-D showed comparable, yet slightly improved performance. Other GAN implementations have been applied to the MB or TCGA cohorts in the past, addressing different aims such as the generation of missing data ⁵⁶, the identification of multi-omics signatures ⁵⁷ and prognostication ⁵⁸. While showing encouraging results, these prior works limited the follow up time to 5 years and focused on death events only. Besides considering longer follow up times, the inclusion of progression or recurrence events in the class definition can be considered a more exhaustive assessment of a patient's risk category, since OS or DSS alone may be insufficient especially in early stage screenings ⁵⁹. In addition, short follow up times were shown to affect the prognostication

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

performance of ML algorithms leading to low sensitivity, mostly due to the insufficient occurrence of recurrence or death events ⁶⁰. We demonstrated that the conversion of transcriptome profiles into images allowed the integration of independent transcriptome datasets. To date, the majority of gene expression databases cannot be directly integrated due to different sequencing technologies, protocols or batch effects, with the consequence of producing merely qualitative results in a meta-analysis fashion or unveiling evidences that remain cohort-specific ⁶¹. To test if our conversion strategy could allow a straightforward integration of heterogenous datasets, we challenged the T-GAN-D in assessing the risk category of MB patients, training the network with a subset of MB patients plus the entire TCGA cohort. Introducing patients belonging to a different cohort improved the performance of the classifier, which in our case outperformed established clinical biomarkers and a published ROR-P signature ⁹ in uni- and multi-variate analyses. The T-GAN-D classifier also stratified early stage breast cancer patients into low and high risk groups, even though no additional factors such as treatment regimens, age, subtype or other clinical features were considered when composing the training datasets. Early stage patients expected to experience recurrence or progression may benefit from more frequent screenings, yet it remains to be assessed if the transcriptome-based classifier operates independently of or correlates with other established risk factors. High accuracy in predicting the risk class of the smaller and imbalanced TCGA cohort was achieved when training the T-GAN-D with a subset of TCGA patients plus the whole MB dataset. Classical ML algorithms (SVM and random forest, among others) were also shown to benefit from the combination of TCGA RNA-Seq and MB microarray data, which in a previous study improved 5 years OS prognostication ⁶², but lead to misleadingly high accuracy due to highly imbalanced classes. Taken together, our results suggest that the T-GAN-D remains robust when merging cohorts differently balanced between positive and negative outcomes, and that the network is still able to capture relevant risk patterns when one

cohort is heavily underrepresented in the training dataset. Therefore, our classification framework may allow the integration of new, smaller datasets, lending itself as a suitable prototype for generating prospective personalized outcome predictions for scarce de novo data. In conclusion, our proof-of-concept study represents an avenue for developing a scalable data augmentation-based tool that could be a stepping stone towards individualized prognosis in the future. Molecular high throughput techniques are increasing in quality, resolution and amount of data produced and are more and more commonly captured in clinical research and diagnostic environments. It was estimated that within the next decade, between 2 and 40 exabytes of genomic data will be generated every year ⁶³, with large quantities being related to human health and disease. GAN-based approaches therefore could become a meaningful approach to exploit such data for the benefit of patients. In addition, -omics domains other than transcriptomics likewise have the potential to enter the clinical arena as part of routine analytical practice, including proteome, metabolome or lipidome data. Such data classes can readily be integrated with clinical-pathological information ⁶⁴, and could be processed with the assistance of GAN based approaches to improve patient-tailored interventions or prognostication.

Acknowledgements

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

MR and CG receive funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2075 – 390740016 and acknowledge the support by the Stuttgart Center for Simulation Science (SimTech).

References

1. Breast cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. (Accessed: 30th August 2022)

- 391 2. Yersal, O. & Barutca, S. Biological subtypes of breast cancer: Prognostic and
- therapeutic implications. World J. Clin. Oncol. 5, 412 (2014).
- 393 3. Turashvili, G. & Brogi, E. Tumor heterogeneity in breast cancer. Front. Med. 4, 227
- 394 (2017).
- 395 4. Cardoso, F. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage
- 396 Breast Cancer. N. Engl. J. Med. 375, 717–729 (2016).
- 397 5. Syed, Y. Y. Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-
- 398 Stage Breast Cancer. *Mol. Diagnosis Ther.* **24**, 621–632 (2020).
- 399 6. Van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast
- 400 cancer. *Nat.* 2002 4156871 **415**, 530–536 (2002).
- 401 7. Arc, M. et al. A Gene-Expression Signature as a Predictor of Survival in Breast
- 402 Cancer. https://doi.org/10.1056/NEJMoa021967 **347**, 1999–2009 (2002).
- 8. Bernard, P. S. et al. Supervised risk predictor of breast cancer based on intrinsic
- 404 subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
- 405 9. Xia, Y., Fan, C., Hoadley, K. A., Parker, J. S. & Perou, C. M. Genetic determinants of
- the molecular portraits of epithelial cancers. *Nat. Commun.* 2019 101 10, 1–13 (2019).
- 407 10. Buus, R. et al. Validation of the OncoMASTR risk score in estrogen receptor-
- positive/HER2-negative patients: A TransATAC study. *Clin. Cancer Res.* **26**, 623–631
- 409 (2020).
- 410 11. Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L. & Hortobágyi, G. N.
- Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer.
- 412 *Oncologist* **13**, 477–493 (2008).
- 413 12. Yao, K., Tong, C. Y. & Cheng, C. A framework to predict the applicability of
- 414 Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer
- 415 prognostic prediction. *Sci. Reports* 2022 121 **12**, 1–11 (2022).
- 416 13. Kelly, C. M. et al. Comparison of the prognostic performance between OncoMasTR

- and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative,
- lymph node-negative breast cancer.
- 419 https://doi.org/10.1200/JCO.2018.36.15_suppl.12074 **36**, 12074–12074 (2018).
- 420 14. Jensen, M. B. et al. The Prosigna gene expression assay and responsiveness to adjuvant
- cyclophosphamide-based chemotherapy in premenopausal high-risk patients with
- breast cancer. Breast Cancer Res. 20, (2018).
- 423 15. Tran, K. A. et al. Deep learning in cancer diagnosis, prognosis and treatment selection.
- 424 *Genome Med.* 2021 131 **13**, 1–17 (2021).
- 425 16. Sharma, A., Vans, E., Shigemizu, D., Boroevich, K. A. & Tsunoda, T. DeepInsight: A
- methodology to transform a non-image data to an image for convolution neural
- 427 network architecture. *Sci. Reports* 2019 91 **9**, 1–7 (2019).
- 428 17. Liu, R. & Gillies, D. F. Overfitting in linear feature extraction for classification of
- high-dimensional image data. *Pattern Recognit.* **53**, 73–86 (2016).
- 430 18. Barandela, R., Valdovinos, R. M., Salvador Sánchez, J. & Ferri, F. J. The imbalanced
- 431 training sample problem: under or over sampling? Lect. Notes Comput. Sci. (including
- 432 Subser. Lect. Notes Artif. Intell. Lect. Notes Bioinformatics) 3138, 806–814 (2004).
- 433 19. Raghu, V. K., Ge, X., Chrysanthis, P. K. & Benos, P. V. Integrated Theory- and Data-
- driven Feature Selection in Gene Expression Data Analysis. *Proceedings. Int. Conf.*
- 435 Data Eng. **2017**, 1525 (2017).
- 436 20. Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic
- 437 Minority Over-sampling Technique. J. Artif. Intell. Res. 16, 321–357 (2011).
- 438 21. Goodfellow, I. et al. Generative Adversarial Networks. Commun. ACM 63, 139–144
- 439 (2014).
- 440 22. Shorten, C. & Khoshgoftaar, T. M. A survey on Image Data Augmentation for Deep
- 441 Learning. J. Big Data 6, 1–48 (2019).
- 442 23. Bowles, C. et al. GAN Augmentation: Augmenting Training Data using Generative

- 443 Adversarial Networks. (2018). doi:10.48550/arxiv.1810.10863
- 444 24. Li, X. et al. When medical images meet generative adversarial network: recent
- development and research opportunities. *Discov. Artif. Intell.* 2021 11 1, 1–20 (2021).
- 446 25. Xiao, Y., Wu, J. & Lin, Z. Cancer diagnosis using generative adversarial networks
- based on deep learning from imbalanced data. *Comput. Biol. Med.* **135**, 104540 (2021).
- 448 26. Wei, K., Li, T., Huang, F., Chen, J. & He, Z. Cancer classification with data
- augmentation based on generative adversarial networks. Front. Comput. Sci. 2022 162
- **16**, 1–11 (2021).
- 451 27. Kwon, C. H., Park, S., Ko, S. & Ahn, J. Increasing prediction accuracy of pathogenic
- staging by sample augmentation with a GAN. *PLoS One* **16**, e0250458 (2021).
- 453 28. Yang, H., Chen, R., Li, D. & Wang, Z. Subtype-GAN: a deep learning approach for
- 454 integrative cancer subtyping of multi-omics data. *Bioinformatics* **37**, 2231–2237
- 455 (2021).
- 456 29. Mukherjee, A. et al. Associations between genomic stratification of breast cancer and
- 457 centrally reviewed tumour pathology in the METABRIC cohort. npj Breast Cancer
- 458 *2018 41* **4**, 1–9 (2018).
- 459 30. The Cancer Genome Atlas Program NCI. Available at:
- https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga.
- 461 (Accessed: 30th August 2022)
- 462 31. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles
- using the cBioPortal. Sci. Signal. 6, (2013).
- 464 32. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring
- multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–4 (2012).
- 466 33. Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive
- genomic subgroups. *Nature* **567**, 399–404 (2019).
- 468 34. Liu, J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-

- 469 Quality Survival Outcome Analytics. *Cell* **173**, 400-416.e11 (2018).
- 470 35. Gendoo, D. M. A. et al. MetaGxData: Clinically Annotated Breast, Ovarian and
- Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene
- 472 Signature. *Sci. Rep.* **9**, (2019).
- 473 36. Guttà, C., Morhard, C. & Rehm, M. T-GAN-D: a GAN-based classifier for breast
- 474 cancer prognostication. (2022). doi:10.5281/ZENODO.7151831
- 475 37. Troester, M. A. et al. Racial Differences in PAM50 Subtypes in the Carolina Breast
- 476 Cancer Study. *JNCI J. Natl. Cancer Inst.* **110**, 176–182 (2018).
- 38. Sweeney, C. et al. Intrinsic subtypes from PAM50 gene expression assay in a
- population-based breast cancer cohort: Differences by age, race, and tumor
- characteristics. Cancer Epidemiol. Biomarkers Prev. 23, 714 (2014).
- 480 39. Arjovsky, M., Chintala, S. & Bottou, L. Wasserstein GAN. (2017). Available at:
- 481 https://arxiv.org/abs/1701.07875v3. (Accessed: 1st March 2022)
- 482 40. Gulrajani, I., Ahmed, F., Arjovsky, M., Dumoulin, V. & Courville, A. Improved
- 483 Training of Wasserstein GANs. Adv. Neural Inf. Process. Syst. 2017-December, 5768–
- 484 5778 (2017).
- 485 41. Odena, A., Olah, C. & Shlens, J. Conditional Image Synthesis With Auxiliary
- 486 Classifier GANs. 34th Int. Conf. Mach. Learn. ICML 2017 6, 4043–4055 (2016).
- 42. Mirza, M. & Osindero, S. Conditional Generative Adversarial Nets. (2014). Available
- 488 at: https://arxiv.org/abs/1411.1784v1. (Accessed: 1st March 2022)
- 489 43. Kodali, N., Abernethy, J., Hays, J. & Kira, Z. On Convergence and Stability of GANs.
- 490 (2017). Available at: https://arxiv.org/abs/1705.07215v5. (Accessed: 1st March 2022)
- 491 44. Radford, A., Metz, L. & Chintala, S. Unsupervised Representation Learning with Deep
- 492 Convolutional Generative Adversarial Networks. 4th Int. Conf. Learn. Represent. ICLR
- 493 *2016 Conf. Track Proc.* (2015).
- 494 45. Ioffe, S. & Szegedy, C. Batch Normalization: Accelerating Deep Network Training by

- 495 Reducing Internal Covariate Shift. 32nd Int. Conf. Mach. Learn. ICML 2015 1, 448–
- 496 456 (2015).
- 497 46. Craven, K. E., Gökmen-Polar, Y. & Badve, S. S. CIBERSORT analysis of TCGA and
- 498 METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
- 499 *Sci. Reports 2021 111* **11**, 1–19 (2021).
- 500 47. Wallis, C. How Artificial Intelligence Will Change Medicine. *Nature* **576**, S48 (2019).
- 501 48. Zhang, C. et al. Cancer diagnosis with DNA molecular computation. Nat. Nanotechnol.
- 502 *2020 158* **15**, 709–715 (2020).
- 503 49. Jia, D. et al. Breast Cancer Case Identification Based on Deep Learning and
- Bioinformatics Analysis. Front. Genet. 12, 767 (2021).
- 505 50. McKinney, S. M. et al. International evaluation of an AI system for breast cancer
- screening. *Nat.* 2020 5777788 **577**, 89–94 (2020).
- 507 51. Desai, S. D., Giraddi, S., Verma, N., Gupta, P. & Ramya, S. Breast Cancer Detection
- Using GAN for Limited Labeled Dataset. Proc. 2020 12th Int. Conf. Comput. Intell.
- 509 Commun. Networks, CICN 2020 34–39 (2020). doi:10.1109/CICN49253.2020.9242551
- 510 52. Liñares-Blanco, J., Pazos, A. & Fernandez-Lozano, C. Machine learning analysis of
- 511 TCGA cancer data. *PeerJ Comput. Sci.* **7**, 1–47 (2021).
- 51.2 53. Liu, B., Wei, Y., Zhang, Y. & Yang, Q. Deep neural networks for high dimension, low
- sample size data. in *IJCAI International Joint Conference on Artificial Intelligence*
- 514 2287–2293 (2017). doi:10.24963/ijcai.2017/318
- 515 54. He, K., Zhang, X., Ren, S. & Sun, J. Delving deep into rectifiers: Surpassing human-
- level performance on imagenet classification. in *Proceedings of the IEEE International*
- 517 *Conference on Computer Vision* **2015 Inter**, 1026–1034 (2015).
- 518 55. Shams, S., Platania, R., Zhang, J., Kim, J. & Park, S. J. Deep generative breast cancer
- 519 screening and diagnosis. in Lecture Notes in Computer Science (including subseries
- Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 11071

- 521 **LNCS**, 859–867 (Springer Verlag, 2018).
- 522 56. Arya, N. & Saha, S. Generative Incomplete Multi-View Prognosis Predictor for Breast
- 523 Cancer: GIMPP. *IEEE/ACM Trans. Comput. Biol. Bioinforma.* 1–1 (2021).
- 524 doi:10.1109/TCBB.2021.3090458
- 525 57. Kim, M., Oh, I. & Ahn, J. An Improved Method for Prediction of Cancer Prognosis by
- 526 Network Learning. *Genes (Basel)*. **9**, 1. 11 (2018).
- 527 58. Hsu, T. C. & Lin, C. Generative Adversarial Networks for Robust Breast Cancer
- 528 Prognosis Prediction with Limited Data Size. Proc. Annu. Int. Conf. IEEE Eng. Med.
- 529 *Biol. Soc. EMBS* **2020-July**, 5669–5672 (2020).
- 530 59. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V. & Fotiadis, D. I.
- Machine learning applications in cancer prognosis and prediction. *Comput. Struct.*
- 532 *Biotechnol. J.* **13**, 8–17 (2015).
- 533 60. Boeri, C. et al. Machine Learning techniques in breast cancer prognosis prediction: A
- primary evaluation. *Cancer Med.* **9**, 3234 (2020).
- 535 61. Carnielli, C. M. et al. Combining discovery and targeted proteomics reveals a
- prognostic signature in oral cancer. *Nat. Commun.* **9**, 3598 (2018).
- 537 62. Dubourg-Felonneau, G. et al. A Framework for Implementing Machine Learning on
- Omics Data. (2018). doi:10.48550/arxiv.1811.10455
- 539 63. Stephens, Z. D. et al. Big Data: Astronomical or Genomical? PLoS Biol. 13, (2015).
- 540 64. Karczewski, K. J. & Snyder, M. P. Integrative omics for health and disease. *Nat. Rev.*
- 541 *Genet.* **19**, 299 (2018).
- 544 Figure legends

543

- Fig. 1. MB and TCGA patient demographics and survival
- 546 (A) Patients demographics of the MB subcohort. (B) Patients demographics of the TCGA

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

subcohort. (C) Overall and (D) relapse-free, progression-free or disease specific survival of the MB and TCGA cohorts. (E) Kaplan Meier curves comparing low vs high risk patients of the MB and (**F**) the TCGA cohorts. Fig. 2. The T-GAN-D robustly stratifies low and high risk breast cancer patients (A) Workflow of the data processing, including the schematics of the generator network and its adversary, the discriminator network. Together these result in an AC-WGAN-GP architecture. After the conversion of patient transcriptome profiles into images, 4/5 of the MB dataset was used to train the GAN's discriminator. After 1000 epochs, the trained discriminator was used as a standalone classifier to separate the remaining 1/5 patients of the dataset into low and high risk categories. (B) Kaplan-Meier curves separating low vs. high risk patients as predicted with the T-GAN-D (iteration 1 of the 5-fold CV shown as representative). (C) Kaplan-Meier curves generated pooling the category predictions obtained for all patients of the MB dataset after five independent CV runs. (**D**) Separation of low vs. high risk patients predicted with a classical CNN on the same subset used in **B** and (**E**) comparison obtained pooling the predictions of five independent CV runs. The area between the curves (ABC) between Low risk (blue dashed line) and Predicted low risk (solid blue line), Predicted low risk and Predicted high risk (solid red line), Predicted high risk and High risk groups (dashed red line) are shown top to bottom in **D** and **E**. Fig. 3. Introducing the independent TCGA cohort improves MB patient classification (A) Schematic representing the training strategy: rescaled data from the entire TCGA cohort were merged with 4/5 of the MB cohort to train the T-GAN-D, which was subsequently used to predict the risk class of the remaining 1/5 of MB patients. The process was iterated 5 times. (B) Kaplan-Meier curves based on the pooled predictions of the T-GAN-D trained on both cohorts. (C) Kaplan-Meier curves separating low vs. high risk patients predicted with the

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

CNN that was trained after merging the MB and the TCGA cohorts. The area between the curves (ABC) between Low risk (blue dashed line) and Predicted low risk (solid blue line), Predicted low risk and Predicted high risk (solid red line), Predicted high risk and high risk groups (dashed red line) are shown top to bottom in **B** and **C**. Fig. 4 The T-GAN-D outperforms classical biomarkers after merging the MB and TCGA cohorts and significantly stratifies early stage MB patients (A) Comparison of the hazard ratios (Cox model, univariate) of a multi-transcript signature (ROR-P) and established prognostic biomarkers (ER, HER2, PR) vs. the CNN and the T-GAN-D before and after cohort merging. (B) Multivariate Cox hazard ratio of the T-GAN-D compared to ROR-P and receptor status and (C) disease stage. (D) Kaplan -Meier curves of Stage I and (E) Stage II patients stratified by the T-GAN-D into low and high risk categories. Fig. 5 The T-GAN-D stratifies TCGA patients despite these being scarcely represented in the merged training set (A) Schematic representing the training strategy: rescaled data from the entire MB cohort were merged with 4/5 of the TCGA cohort to train the T-GAN-D, which was subsequently used to predict the risk class of the remaining 1/5 of TCGA patients. The process was iterated 5 times. (B) Stratification of the TCGA patients by T-GAN-D trained on the merged dataset and (C) the MB dataset alone. Kaplan-Meier curves were generated pooling the predictions of all iterations of the 5-fold CV. The area between the curves (ABC) between Low risk (blue dashed line) and Predicted low risk (solid blue line), Predicted low risk and Predicted high risk (solid red line), Predicted high risk and High risk groups (dashed red line) are shown top to bottom in **B** and **C**.

METABRIC sub-cohort (n = 1248)

METADINO 300-conort (II - 12	70)	
Age at diagnosis (years)	# cases	%
<40	83	6.7
40-49	188	15.1
50-59	288	23.1
60-69	392	31.4
70-79	235	18.8
80+	62	5.0
Disease Stage	# cases	%
Stage I	303	24.3
Stage II	514	41.2
Stage III	88	7.1
Stage IV	8	0.6
Not available	335	26.8
Survival (months)	Median	
Overall survival	163.2	


160.2

В


BRCA-TCGA sub-cohort (n = 165)

BRCA-TCGA sub-conort (n = 165)		
Age at diagnosis (years)	# cases	%
<40	20	12.1
40-49	38	23.0
50-59	29	17.6
60-69	44	26.7
70-79	22	13.3
80+	12	7.3
Disease Stage	# cases	%
Stage I	22	13.3
Stage II	72	43.6
Stage III	50	30.3
Stage IV	14	8.5
Not available	7	4.2
Survival (months)	Median	
Overall survival	92	
Progression or disease specific death	35.5	


C





Relapse or disease specific death




D Relapse-free, progression-free or disease specific survival















12 24 36 48 60 72 84 96 108 120

Time to relapse or disease specific death (months)

12 24 36 48 60 72 84 96 108 120

Time to relapse or disease specific death (months)



12 24 36 48 60 72 84 96 108 120 Time to relapse or disease specific death (months) 12 24 36 48 60 72 84 96 108 120

Time to relapse or disease specific death (months)

Fig. 4

